Gastric Inhibitory Polypeptide
"Gastric Inhibitory Polypeptide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A gastrointestinal peptide hormone of about 43-amino acids. It is found to be a potent stimulator of INSULIN secretion and a relatively poor inhibitor of GASTRIC ACID secretion.
| Descriptor ID |
D005749
|
| MeSH Number(s) |
D06.472.317.400 D06.472.699.275 D12.644.400.300 D12.644.548.275 D12.776.631.650.300
|
| Concept/Terms |
Gastric Inhibitory Polypeptide- Gastric Inhibitory Polypeptide
- Inhibitory Polypeptide, Gastric
- Polypeptide, Gastric Inhibitory
- Glucose-Dependent Insulin-Releasing Peptide
- Glucose Dependent Insulin Releasing Peptide
- Insulin-Releasing Peptide, Glucose-Dependent
- Peptide, Glucose-Dependent Insulin-Releasing
- Glucose Dependent Insulinotropic Peptide
- Glucose-Dependent Insulinotropic Peptide
- Insulinotropic Peptide, Glucose-Dependent
- Peptide, Glucose-Dependent Insulinotropic
- Gastric-Inhibitory Polypeptide
- Polypeptide, Gastric-Inhibitory
|
Below are MeSH descriptors whose meaning is more general than "Gastric Inhibitory Polypeptide".
Below are MeSH descriptors whose meaning is more specific than "Gastric Inhibitory Polypeptide".
This graph shows the total number of publications written about "Gastric Inhibitory Polypeptide" by people in this website by year, and whether "Gastric Inhibitory Polypeptide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Gastric Inhibitory Polypeptide" by people in Profiles.
-
Kelly MS, Scopelliti EM, Goodson KE, Lo CMA, Nguyen HX, Simon B. Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2024 12; 26(12):5661-5668.
-
Jabbour S, Paik JS, Aleppo G, Sharma P, Gomez Valderas E, Benneyworth BD. Switching to Tirzepatide 5?mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment. Endocr Pract. 2024 Aug; 30(8):701-709.
-
Danowitz M, De Leon DD. The Role of GLP-1 Signaling in Hypoglycemia due to Hyperinsulinism. Front Endocrinol (Lausanne). 2022; 13:863184.
-
Encina G, Ezquer F, Conget P, Israel Y. Insulin is secreted upon glucose stimulation by both gastrointestinal enteroendocrine K-cells and L-cells engineered with the preproinsulin gene. Biol Res. 2011; 44(3):301-5.
-
Hoo RL, Chu JY, Yuan Y, Yeung CM, Chan KY, Chow BK. Functional identification of an intronic promoter of the human glucose-dependent insulinotropic polypeptide gene. Gene. 2010 Sep 01; 463(1-2):29-40.
-
Sarson DL, Kopelman PG, Besterman HS, Pilkington TR, Bloom SR. Disparity between glucose-dependent insulinotropic polypeptide and insulin responses in obese man. Diabetologia. 1983 Nov; 25(5):386-91.